Sanofi: Sanofi & Regeneron's Dupixent receives Japanese marketing approval to treat patients with COPD
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults
Read full article »
Sanofi is a France-based healthcare firm that develops and markets pharmaceutical drugs and OTC medicines for the treatment of a range of diseases such as diabetes and cancer.
Read more